LOUISVILLE, Ky. & LOS ANGELES--(BUSINESS WIRE)--Integration of a substance abuse treatment program into population-based
behavioral care helped improve health outcomes and 1 Day Drug Detox in Kentucky lower costs according
to a peer-reviewed, retrospective cohort study released this week by
Humana Inc. (NYSE: HUM) and Catasys Inc. (CATS) at the American Society
of Addiction Medicine annual conference.
According to the National Survey on Drug Use and Health, approximately 23
million Americans need treatment for a substance abuse disorder
(SUD). However, less than 11% receive treatment. This present approach
creates a passive system, wherein over 20 million people who may benefit
from substance abuse treatment (SAT) are overlooked.
http://www.youtube.com/watch?v=Fe0w2ALIAgc
To create a more proactive approach, Humana integrated an SAT program
with Catasys into its population-based behavioral health efforts. The
program used claims-based analytics to identify individuals at risk for
medical and psychiatric complications from substance abuse and
proactively engaged them in treatment and care coaching over a 52-week
period.
The objective of the Humana/Catasys study was to compare changes in
emergency room (ER) visits and inpatient hospitalizations for
participants in the SAT program and changes in total cost of care among
participants in the SAT program versus eligible individuals who did not
participate (non-participants).
"The improved health outcomes results clearly reflect the benefits that
population health can achieve by integrating substance abuse programs,"
said Dr. Larry Weinstein, Chief Medical Officer for LifeSynch, a wholly
owned subsidiary of Humana that provides behavioral health services. "By
taking a proactive approach, as opposed to a reactive one, we were able
to reach people at risk for medical and psychiatric complications from
substance use disorders. This enabled us to take the necessary steps to
help people improve their health."
Study Findings
Key findings from the Humana/Catasys study include:
Proactive, integrated, population-based approach to substance abuse
program enrollment resulted in a 17.6% enrollment rate, compared to
the national average of 10.9%;
Participants had 16% fewer ER visits and 67% fewer inpatient
hospitalizations than before beginning the program; and
Health care costs dropped an average of 46% for the participant group,
whereas non-participant costs increased an average of 14%.
"We are pleased to help members with substance use disorders engage the
type of support needed to improve their health and well-being," said
Omar Manejwala, M.D., Chief Medical Officer for Catasys. "Treated
members are proactively managing their conditions, and their improved
health results in fewer trips to the emergency room and fewer inpatient
admissions."
Study Methodology
The Humana/Catasys study population included 151 participants and 2,198
matched non-participants. The mean age of the participant cohort was 59
years old.
Eligible individuals were identified by a medical claims history of SUD,
elevated claims threshold, and absence of exclusionary diagnoses such as
cancer and transplants. For the Humana/Catasys study, participants were
matched to eligible non-participants based on a score from an algorithm
used to estimate medical condition severity and functionality.
Humana/Catasys study outcomes were measured over the duration of the
program, which occurred between November 1, 2013 and October 31, 2014.
As an indicator of health status, the mean number of ER visits and
inpatient admissions per person and the mean length of stay were
calculated using claims data and compared between the participants
before and after participation in the SAT program. Costs were reported
as changes in average allowed claims costs per member per month for both
the participant and non-participant groups.
Humana and Catasys presented these findings at the American Society of
Addiction Medicine 46th annual conference, which took place April 23-26,
2015 in Austin, TX.
About Humana
Humana Inc., headquartered in Louisville, Ky., is a leading health and
well-being company focused on making it easy for people to achieve their
best health with clinical excellence through coordinated care. The
company's strategy integrates care delivery, the member experience, and
clinical and consumer insights to encourage engagement, behavior change,
proactive clinical outreach and wellness for the millions of people we
serve across the country.
More information regarding Humana is available to investors via the
Investor Relations page of the company's web site at www.humana.com,
including copies of:
Annual reports to stockholders;
Securities and Exchange Commission filings;
Most recent investor conference presentations;
Quarterly earnings news releases;
Replays of most recent earnings release conference calls;
Calendar of events (including upcoming earnings conference call dates
and times, as well as planned interaction with research analysts and
institutional investors);
Corporate Governance information.
About Catasys
Catasys, Inc. provides specialized healthcare management services to
health plans and employers through its OnTrak program. Catasys' OnTrak
program--contracted with a growing number of health insurers--is designed
to improve member health and, at the same time, lower costs to the
insurer for underserved populations where behavioral health conditions
cause or exacerbate co-existing medical conditions. The program utilizes
analytics to engage members in need of care and patient-centric
treatment that integrates evidence-based medical and psychosocial
interventions along with care coaching in a 52-week outpatient program.
OnTrak is currently improving member health and, at the same
time, is demonstrating reduced inpatient and emergency room utilization,
driving a more than 50 percent reduction in total health insurers' costs
for enrolled members. Catasys currently operates OnTrak in
Florida, Kansas, Kentucky, Louisiana, Massachusetts, New Jersey,
Oklahoma, West Virginia and Wisconsin. For further information, please
visit catasys.com.
